PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
35470044-1	2022	Cyp2c70-/- mice with a human-like bile acid (BA) composition, lacking hydrophilic muricholic acids (MCAs), have been reported to display cholangiopathy and biliary fibrosis with female preponderance that can be reversed by ursodeoxycholic acid (UDCA).	Bile Acids and Salts	34-43	cytochrome P450, family 2, subfamily c, polypeptide 70	Mus musculus	0-7	
35470044-1	2022	Cyp2c70-/- mice with a human-like bile acid (BA) composition, lacking hydrophilic muricholic acids (MCAs), have been reported to display cholangiopathy and biliary fibrosis with female preponderance that can be reversed by ursodeoxycholic acid (UDCA).	Bile Acids and Salts	45-47	cytochrome P450, family 2, subfamily c, polypeptide 70	Mus musculus	0-7	
35470044-1	2022	Cyp2c70-/- mice with a human-like bile acid (BA) composition, lacking hydrophilic muricholic acids (MCAs), have been reported to display cholangiopathy and biliary fibrosis with female preponderance that can be reversed by ursodeoxycholic acid (UDCA).	muricholic acid	82-98	cytochrome P450, family 2, subfamily c, polypeptide 70	Mus musculus	0-7	
35470044-1	2022	Cyp2c70-/- mice with a human-like bile acid (BA) composition, lacking hydrophilic muricholic acids (MCAs), have been reported to display cholangiopathy and biliary fibrosis with female preponderance that can be reversed by ursodeoxycholic acid (UDCA).	Ursodeoxycholic Acid	223-243	cytochrome P450, family 2, subfamily c, polypeptide 70	Mus musculus	0-7	
35470044-1	2022	Cyp2c70-/- mice with a human-like bile acid (BA) composition, lacking hydrophilic muricholic acids (MCAs), have been reported to display cholangiopathy and biliary fibrosis with female preponderance that can be reversed by ursodeoxycholic acid (UDCA).	Ursodeoxycholic Acid	245-249	cytochrome P450, family 2, subfamily c, polypeptide 70	Mus musculus	0-7	
35470044-2	2022	Obeticholic acid (OCA), a steroidal BA-like FXR agonist, has been shown to improve liver function in patients with primary biliary cholangitis and is approved as second-line treatment for patients with an inadequate response or intolerance to UDCA.	obeticholic acid	0-16	nuclear receptor subfamily 1 group H member 4	Homo sapiens	44-47	
35470044-2	2022	Obeticholic acid (OCA), a steroidal BA-like FXR agonist, has been shown to improve liver function in patients with primary biliary cholangitis and is approved as second-line treatment for patients with an inadequate response or intolerance to UDCA.	obeticholic acid	18-21	nuclear receptor subfamily 1 group H member 4	Homo sapiens	44-47	
35470044-7	2022	In Cyp2c70-/- mice, however, BA pool became more hydrophobic with a larger proportion of chenodeoxycholic acid, attributable to a reduction of BA 12alpha-hydroxylation.	Bile Acids and Salts	29-31	cytochrome P450, family 2, subfamily c, polypeptide 70	Mus musculus	3-10	
35470044-7	2022	In Cyp2c70-/- mice, however, BA pool became more hydrophobic with a larger proportion of chenodeoxycholic acid, attributable to a reduction of BA 12alpha-hydroxylation.	Chenodeoxycholic Acid	89-110	cytochrome P450, family 2, subfamily c, polypeptide 70	Mus musculus	3-10	
35470044-7	2022	In Cyp2c70-/- mice, however, BA pool became more hydrophobic with a larger proportion of chenodeoxycholic acid, attributable to a reduction of BA 12alpha-hydroxylation.	Bile Acids and Salts	143-145	cytochrome P450, family 2, subfamily c, polypeptide 70	Mus musculus	3-10	
35470044-11	2022	In conclusion, 4 weeks of OCA treatment oppositely modulates the hydrophobicity of the BA pool in WT and Cyp2c70-/- mice, but does not improve or worsen the characteristic sex-dependent liver pathology in Cyp2c70-/- mice.	obeticholic acid	26-29	cytochrome P450, family 2, subfamily c, polypeptide 70	Mus musculus	105-112	
35470044-11	2022	In conclusion, 4 weeks of OCA treatment oppositely modulates the hydrophobicity of the BA pool in WT and Cyp2c70-/- mice, but does not improve or worsen the characteristic sex-dependent liver pathology in Cyp2c70-/- mice.	Bile Acids and Salts	87-89	cytochrome P450, family 2, subfamily c, polypeptide 70	Mus musculus	105-112